{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:44:44Z","timestamp":1769121884709,"version":"3.49.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1602,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>While the efficacy of the intracardiac defibrillators (ICDs) for primary prevention is not disputed, the relevant studies were carried out a long time ago. Most pertinent trials, including MADIT-II, SCD-Heft, and DEFINITE, recruited patients more than 20 years ago. Since then, improved therapeutic modalities including, in addition to cardiac resynchronization therapy, mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitors, and, most recently, inhibitors of sodium-glucose cotransporter 2, have lowered present-day rates of mortality and of sudden cardiac death. Thus, nowadays, ICD therapy may be less effective than previously reported, and not as beneficial as many people currently believe. However, criteria for ICD implantation remain very inclusive. The patient must (only) be symptomatic and have ejection fraction (EF) \u2264 35%. The choice of EF 35% is notable because the average EF in all large trials was much lower, and clinical benefit was mainly limited to EF \u2264 30%. This EF cut-off value defines a substantial portion of potential ICD recipients. It seems therefore reasonable to limit ICD eligibility criteria in the EF range 30\u201335% to patients at highest risk only. We discuss and present some rational criteria to assist the clinician in improving risk stratification for preventive ICD implantation.<\/jats:p>","DOI":"10.1002\/ehf2.13506","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T01:48:36Z","timestamp":1627868916000},"page":"3656-3662","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preventive Implantable Cardioverter Defibrillator Therapy in Contemporary Clinical Practice: Need for More Stringent Selection Criteria"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-7254","authenticated-orcid":false,"given":"Jaap W.","family":"Deckers","sequence":"first","affiliation":[{"name":"Department of Cardiology, Thoraxcenter, Erasmus Medical Center Rotterdam , Dr. Molewaterplein 40, Rotterdam, 3015 GD ,","place":["The Netherlands"]},{"name":"Department of Epidemiology, Erasmus Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0223-7872","authenticated-orcid":false,"given":"Banafsheh","family":"Arshi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-2785","authenticated-orcid":false,"given":"Jan C.","family":"van den Berge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thoraxcenter, Erasmus Medical Center Rotterdam , Dr. Molewaterplein 40, Rotterdam, 3015 GD ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9556-9536","authenticated-orcid":false,"given":"Alina A.","family":"Constantinescu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thoraxcenter, Erasmus Medical Center Rotterdam , Dr. Molewaterplein 40, Rotterdam, 3015 GD ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,1]]},"reference":[{"key":"2026012114221719500_ehf213506-bib-0001","author":"Asktheicd","year":"2020"},{"key":"2026012114221719500_ehf213506-bib-0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12471-013-0504-x","article-title":"Heart disease in the Netherlands: a quantitative update","volume":"22","author":"Leening","year":"2014","journal-title":"Neth Heart J"},{"key":"2026012114221719500_ehf213506-bib-0003","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4070\/kcj.2018.0444","article-title":"Temporal trends of cardiac implantable electronic device implantations: a nationwide population-based study","volume":"49","author":"Lee","year":"2019","journal-title":"Korean Circ J"},{"key":"2026012114221719500_ehf213506-bib-0004","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators","volume":"335","author":"Moss","year":"1996","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0005","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJM199711273372201","article-title":"Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators","volume":"337","author":"Bigger","year":"1997","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0006","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1056\/NEJM199912163412503","article-title":"A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators","volume":"341","author":"Buxton","year":"1999","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0007","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0008","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa041489","article-title":"Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction","volume":"351","author":"Hohnloser","year":"2004","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0009","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0010","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMoa0901889","article-title":"Defibrillator implantation early after myocardial infarction","volume":"361","author":"Steinbeck","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609758","article-title":"Declining risk of sudden death in heart failure","volume":"377","author":"Shen","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0012","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"Kober","year":"2016","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0013","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.0000012350.99718.AD","article-title":"Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT)","volume":"105","author":"Bansch","year":"2002","journal-title":"Circulation"},{"key":"2026012114221719500_ehf213506-bib-0014","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0735-1097(03)00297-3","article-title":"Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia\u2014AMIOVIRT","volume":"41","author":"Strickberger","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026012114221719500_ehf213506-bib-0015","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa033088","article-title":"Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy","volume":"350","author":"Kadish","year":"2004","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0016","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0017","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114221719500_ehf213506-bib-0018","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0019","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0020","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0021","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114221719500_ehf213506-bib-0022","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.jacc.2006.03.032","article-title":"The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II","volume":"47","author":"Zwanziger","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026012114221719500_ehf213506-bib-0023","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000198","article-title":"A systematic review of ICD complications in randomised controlled trials versus registries: is our \u2018real-world\u2019 data an underestimation?","volume":"2","author":"Ezzat","year":"2015","journal-title":"Open Heart"},{"key":"2026012114221719500_ehf213506-bib-0024","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jacc.2011.06.007","article-title":"Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials","volume":"58","author":"van Rees","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026012114221719500_ehf213506-bib-0025","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.hrthm.2015.02.035","article-title":"The clinical course of patients with implantable cardioverter-defibrillators: extended experience on clinical outcome, device replacements, and device-related complications","volume":"12","author":"van der Heijden","year":"2015","journal-title":"Heart Rhythm"},{"key":"2026012114221719500_ehf213506-bib-0026","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M15-2732","article-title":"Long-term risk for device-related complications and reoperations after implantable cardioverter-defibrillator implantation: an observational cohort study","volume":"165","author":"Ranasinghe","year":"2016","journal-title":"Ann Intern Med"},{"key":"2026012114221719500_ehf213506-bib-0027","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/pace.12850","article-title":"Estimating the risks and benefits of implantable cardioverter defibrillator generator replacement: a systematic review","volume":"39","author":"Lewis","year":"2016","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026012114221719500_ehf213506-bib-0028","article-title":"Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy","volume":"12","author":"El Moheb","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012114221719500_ehf213506-bib-0029","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1093\/eurheartj\/ehz773","article-title":"Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review","volume":"41","author":"Barra","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012114221719500_ehf213506-bib-0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.hrthm.2014.09.054","article-title":"Declining incidence of sudden cardiac death from 1990\u20132010 in a general middle-aged and elderly population: the Rotterdam Study","volume":"12","author":"Niemeijer","year":"2015","journal-title":"Heart Rhythm"},{"key":"2026012114221719500_ehf213506-bib-0031","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/eurheartj\/ehi809","article-title":"Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk","volume":"27","author":"Deckers","year":"2006","journal-title":"Eur Heart J"},{"key":"2026012114221719500_ehf213506-bib-0032","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"2026012114221719500_ehf213506-bib-0033","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","article-title":"Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"2026012114221719500_ehf213506-bib-0034","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114221719500_ehf213506-bib-0035","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2010.11.030","article-title":"Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment","volume":"57","author":"Merlo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026012114221719500_ehf213506-bib-0036","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.13299","article-title":"Left ventricular remodelling and prognosis after discharge in new-onset acute heart failure with reduced ejection fraction","author":"van den Berge","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114221719500_ehf213506-bib-0037","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1161\/01.CIR.0000037224.15873.83","article-title":"Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease","volume":"106","author":"Alfred","year":"2002","journal-title":"Circulation"},{"key":"2026012114221719500_ehf213506-bib-0038","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/europace\/eur147","article-title":"Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers","volume":"13","author":"Scott","year":"2011","journal-title":"Europace"},{"key":"2026012114221719500_ehf213506-bib-0039","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/europace\/euu296","article-title":"Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations","volume":"17","author":"Barra","year":"2015","journal-title":"Europace"},{"key":"2026012114221719500_ehf213506-bib-0040","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/heart.89.10.1157","article-title":"QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure","volume":"89","author":"Bode-Schnurbus","year":"2003","journal-title":"Heart"},{"key":"2026012114221719500_ehf213506-bib-0041","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jacc.2005.11.026","article-title":"Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction","volume":"47","author":"Bloomfield","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026012114221719500_ehf213506-bib-0042","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2010.06.062","article-title":"Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death","volume":"57","author":"Iles","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026012114221719500_ehf213506-bib-0043","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jacc.2007.08.058","article-title":"Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction","volume":"51","author":"Goldenberg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026012114221719500_ehf213506-bib-0044","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/j.jacc.2017.03.568","article-title":"Seattle heart failure and proportional risk models predict benefit from implantable cardioverter-defibrillators","volume":"69","author":"Bilchick","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012114221719500_ehf213506-bib-0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2016.09.017","article-title":"Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis","volume":"5","author":"Di Marco","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026012114221719500_ehf213506-bib-0046","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11886-019-1236-3","article-title":"Risk stratification for sudden cardiac death in non-ischaemic dilated cardiomyopathy","volume":"21","author":"Akhtar","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"2026012114221719500_ehf213506-bib-0047","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2017.0630","article-title":"Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: a meta-analysis","volume":"2","author":"Al-Khatib","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026012114221719500_ehf213506-bib-0048","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002744","article-title":"Influence of ejection fraction on outcomes and efficacy of sacubitril\/valsartan (LCZ696) in heart failure with reduced ejection fraction: the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial","volume":"9","author":"Solomon","year":"2016","journal-title":"Circ Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13506","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13506","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/5\/3656\/65566094\/eschf_8_5_3656.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/5\/3656\/65566094\/eschf_8_5_3656.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:27:43Z","timestamp":1769023663000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/5\/3656\/8345826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,8,1]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13506","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10]]},"published":{"date-parts":[[2021,8,1]]},"assertion":[{"value":"2021-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}